Cargando…

Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population

PURPOSE: This randomized, double-blind (DB), non-inferiority phase 3 study was conducted to assess the efficacy and safety of paliperidone palmitate 3-month (PP3M) vs 1-month formulation (PP1M) in European and non-European patients with schizophrenia. PATIENTS AND METHODS: In this randomized, DB, pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Savitz, Adam J, Xu, Haiyan, Gopal, Srihari, Nuamah, Isaac, Ravenstijn, Paulien, Hough, David, Hargarter, Ludger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391122/ https://www.ncbi.nlm.nih.gov/pubmed/30863080 http://dx.doi.org/10.2147/NDT.S189668

Ejemplares similares

Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study
por: Savitz, Adam J., et al.
Publicado: (2016)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
por: Mathews, Maju, et al.
Publicado: (2019)

PM409. Paliperidone Palmitate 3-Monthly vs. 1-Monthly Injectable in Schizophrenia Patients with or without Prior Exposure to Oral Risperidone or Paliperidone
por: Mathews, Maju, et al.
Publicado: (2016)

PM532. Symptomatic Remission and Functional Recovery after Paliperidone Palmitate 3-monthly or 1-monthly treatment in Asian Patients with Exacerbated Schizophrenia
por: Savitz, Adam, et al.
Publicado: (2016)

PM410. Comparison of 3-Monthly versus 1-Monthly Paliperidone Palmitate for Time to Onset and Time to Resolution of Extrapyramidal Symptoms in Patients with Exacerbated Schizophrenia
por: Mathews, Maju, et al.
Publicado: (2016)

Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study
por: Savitz, Adam J, et al.
Publicado: (2017)

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
por: Mathews, Maju, et al.
Publicado: (2018)

Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies
por: Savitz, Adam J., et al.
Publicado: (2019)

Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle: Are They Therapeutically Equivalent?
por: Ravenstijn, Paulien, et al.
Publicado: (2016)

PM511. Determinants of Caregiver Burden in Family Carers of Asian Patients with Schizophrenia treated with Paliperidone Palmitate 3-monthly injectable
por: Srihari, Gopal,, et al.
Publicado: (2016)

PM419. Efficacy and safety of paliperidone palmitate 3-monthly versus 1-monthly formulation in Asian patients with schizophrenia: Subgroup analysis of a randomized, double-blind, noninferiority study
por: Savitz, A, et al.
Publicado: (2016)

PM386. An Assessment of Injection Site Reactions and Injection Site Pain of Once-Every One Month and Three-Month Long-Acting Injectable Formulations of Paliperidone Palmitate
por: Elefant, Erica, et al.
Publicado: (2016)

F230. COMPARISON OF PALIPERIDONE PALMITATE 3-MONTH AND PALIPERIDONE PALMITATE 1-MONTH FORMULATION FOR NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: A PHASE 3 NON-INFERIORITY STUDY
por: Mathews, Maju, et al.
Publicado: (2018)

PM531. Population Pharmacokinetic/Pharmacodynamic Modeling of Paliperidone Palmitate 3-Month Formulation in Asian Population
por: Russu, Alberto, et al.
Publicado: (2016)

Maintenance dose conversion between oral risperidone and paliperidone palmitate 1 month: Practical guidance based on pharmacokinetic simulations
por: Russu, Alberto, et al.
Publicado: (2018)

Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis
por: Li, Gang, et al.
Publicado: (2021)

Population Pharmacokinetics of Paliperidone Palmitate (Once‐Monthly Formulation) in Japanese, Korean, and Taiwanese Patients With Schizophrenia
por: Shimizu, Hiroko, et al.
Publicado: (2019)

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
por: Nash, Abigail I, et al.
Publicado: (2019)

PM480. Early schizophrenia patients treated with once-monthly paliperidone palmitate over a 12-month period - A Retrospective Observational Study
por: Schreiner, Andreas, et al.
Publicado: (2016)

Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies
por: Gopal, Srihari, et al.
Publicado: (2017)

Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study
por: Giron‐Hernandez, Cesar, et al.
Publicado: (2023)

Defining “Adequately Treated”: A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate
por: O’Donnell, Amy, et al.
Publicado: (2021)

Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia
por: Hargarter, L, et al.
Publicado: (2016)

A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia
por: Coppola, Danielle, et al.
Publicado: (2012)

Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia
por: Gopal, Srihari, et al.
Publicado: (2011)

Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia
por: Lambert, Martin, et al.
Publicado: (2020)

Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia
por: Emsley, Robin, et al.
Publicado: (2017)

PALIPERIDONE PALMITATE 6-MONTH FORMULATION FOR THE TREATMENT OF SCHIZOPHRENIA: A 4-MONTH FOLLOW-UP STUDY
por: Romero Guillena, S. L., et al.
Publicado: (2023)

PM479. Clinical and Functional Response to Paliperidone Palmitate in Early Schizophrenia – A Retrospective Observational Study in Newly Diagnosed Patients Treated Over a 12-Month Period
por: Schreiner, Andreas, et al.
Publicado: (2016)

Cognitive functioning in adolescents with schizophrenia treated with paliperidone extended-release: 6-Month exploratory analysis from an open-label, single-arm safety study()
por: Pandina, Gahan, et al.
Publicado: (2020)

Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation
por: Corbeil, Olivier, et al.
Publicado: (2022)

Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes
por: Pungor, Katalin, et al.
Publicado: (2020)

T45. A COMPARISON OF SCHIZOPHRENIA RELAPSE RATES OF 3 PALIPERIDONE FORMULATIONS, ONCE-DAILY, ONCE-MONTHLY AND ONCE EVERY-3-MONTH: POST-HOC ANALYSIS FROM 3 RANDOMIZED CONTROLLED TRIALS
por: Mathews, Maju, et al.
Publicado: (2018)

Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies
por: Gopal, Srihari, et al.
Publicado: (2013)

Are the Long-Acting Intramuscular Formulations of Risperidone or Paliperidone Palmitate Associated with Post-Injection Delirium/Sedation Syndrome? An Assessment of Safety Databases
por: Alphs, Larry, et al.
Publicado: (2011)

Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia
por: Turkoz, Ibrahim, et al.
Publicado: (2023)

PM481. Tolerability, safety and treatment response of flexibly-dosed paliperidone palmitate in patients hospitalized for an exacerbation of schizophrenia
por: Schreiner, Andreas, et al.
Publicado: (2016)

Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose
por: Samtani, Mahesh N, et al.
Publicado: (2013)

A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia
por: Najarian, Dean, et al.
Publicado: (2021)

Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies
por: Mathews, Maju, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jp5ldcpeg4qv7pm8pmkprca313